The American Thyroid Association (ATA) 2025 Annual Meeting is set to take place September 10 through September 14 in Scottsdale, Arizona. As the largest gathering of thyroidologists in the world, the meeting is not only a great opportunity to gain insights into the latest research and emerging technologies, but it is also a world-class opportunity to network with peers from around the world. 

With so many diverse topics to choose from, attendees can pick and choose to attend the sessions that are most relevant to their professional development. Today, we outlined the topics related to thyroid cancer for your convenience. These times are accurate as of August 7, 2025. For a look at the complete schedule and the most up-to-date information, visit the official ATA 2025 annual conference website.

September 11

Oral Abstracts Session 2: Diagnosis of Thyroid Nodules and Cancer

  • 9:25 AM – 10:25 AM
  • Description: This session includes topics such as the diagnosis of thyroid nodules and cancer, the outcomes of the first 100 cases of thyroid nodule microwave ablation in North America, ultrasound and molecular characterization of radiation-induced papillary thyroid cancer in childhood cancer survivors, and more.

Oral Abstracts Session 3: Thyroid Cancer – Novel Treatments

  • 9:25 AM – 10:25 AM
  • Description: This session includes topics such as neoadjuvant treatment with selpercatinib for RET-Altered thyroid cancer, the results of a phase 2 study of neoadjuvant lenvatinib in locally advanced invasive differentiated thyroid cancer, and more.

Oral Abstracts Session 4: Late Breaking Abstracts 1

  • 9:25 – 10:25 AM
  • Description: This session includes topics related to thyroid cancer like exposure to GLP-1RA and risk of structural recurrence in differentiated thyroid cancer, a final update on the safety and efficacy of selpercatinib in first-line patients with RET-fusion positive thyroid cancer, and more.

Neoadjuvant Treatment of Advanced Thyroid Cancer

  • 11:30 AM – 12:30 PM
  • Description: This session will discuss when and how to operate on cancerous nodules, assessing advanced thyroid cancer, and neoadjuvant therapies for various thyroid cancer types.

Networking Session: Thyroid Cancer Disparities and Access to Care: A Closer Look

  • 3:00 PM – 4:00 PM
  • Description: This panel session is set to discuss access to quality care and thyroid cancer disparities. The session will feature three panelists and two co-chairs leading the discussion.

Management of Medullary Thyroid Cancers

  • 4:10 PM – 5:10 PM
  • Description: This session will focus on surgical management techniques, external beam radiation therapy for primary site and distant metastasis, and sequencing systemic therapies in RET and non-RET mutated disease.
September 12

Deciphering New Molecular Targets in Thyroid Cancer

  • 11:30 AM – 12:45 PM
  • Description: Attendees will learn about basic mechanisms of tumor cell migration, the “magic” of the genetic duet of BRAF V600E and TERT promoted mutation in thyroid cancer, and how the reactivation of the developmental factor TBX3 drives BRAF/MAPK-mediated thyroid tumorigenesis.

Thyroid Consequences of Cancer Immune Therapy

  • 11:30 AM – 12:45 PM
  • Description: This session will focus on recognizing and predicting endocrine autoimmune side effects during cancer immunotherapy, understanding the relationship between endocrine immune-related adverse events and cancer immunotherapy outcomes, and more.

Advanced in Combinatorial Drug Strategies to Target Thyroid Cancer

  • 2:00 PM – 3:00 PM
  • Description: This session is set to discuss drug repositioning in thyroid cancer, targeted therapies in pediatric thyroid cancer, and combining TSHR-CART cell therapy with MAPK inhibitors. 

Oral Abstracts Session 6: Thyroid Cancer – Mechanistic Insights

  • 4:10 PM – 5:10 PM
  • Description: Attendees will explore associations between glyphosate exposure and thyroid cancer incidence, how spatial transcriptomics reveal immune microenvironment heterogeneity in differentiated papillary thyroid cancer, and more.

Oral Abstracts Session 7: Late Breaking Abstracts 2

  • 4:10 PM – 5:10 PM
  • Description: Some of the topics presented in this session are related to thyroid cancer, including how Zoledronate prevents anaplastic thyroid cancer bone metastases, emerging trends in aggressive thyroid cancers and associated mortality, and more.
September 13

Anaplastic Thyroid Cancer

  • 9:15 AM – 10:15 AM
  • Description: This session focuses on anaplastic thyroid cancer (ATC) and discusses novel molecular insights into the pathogenesis of ATC, when to operate, and providing personalised treatment to patients. 

Pediatric Symposium

  • 1:00 PM – 5:00 PM
  • Description: Components of this session are related to thyroid cancer including portions discussing applying guidelines for pediatric thyroid cancer and thyroid cancer predisposition in pediatric patients. 

Metabolic Shifts in Thyroid Cancer: Mechanisms and Implications

  • 2:10 PM – 3:10 PM
  • Description: This session will discuss obesity and obesity-related metabolic conditions and risk of thyroid cancer in women, how integrative multi-omics analysis reveals different metabolic phenotypes based on molecular characteristics in thyroid cancer, and more. 

Oral Abstracts Session 8: Clinical & Translational Thyroid Cancer

  • 3:15 PM – 4:15 PM
  • Description: Attendees will learn about an international study of anaplastic thyroid carcinoma from 140 cases from the World Tumor Registry database, a targeted therapy in follicular cell-derived thyroid cancer, among other topics. 

Oral Abstracts Session 9: Disorders of Thyroid Function

  • 3:15 PM – 4:15 PM
  • Description: This session features two topics related to thyroid cancer: radioactive iodine dose-response and predictors of disease-free status in intermediate-risk papillary thyroid cancer, and rates and trends of completion thyroidectomy after lobectomy for thyroid cancer.

Oral Abstracts Session 10: Outcomes of Thyroid Cancer

  • 3:15 PM – 4:15 PM
  • Description: This session discusses how CTR-FAPI PET-guided surgery improves biochemical cure rates in medullary thyroid carcinoma, outcomes of upfront dabrafenib/trametinib prior to initial RAI treatment in BRAFV600E and TERT mutant differentiated papillary thyroid cancer, and more.

Improving Care for Thyroid Cancer Patients

  • 4:30 PM – 5:30 PM
  • Description: Topics planned for this session include obstacles and solutions to patient access, identifying and addressing loss to follow-up during the survivorship period, and more.
September 14

Applying the Guidelines: Thyroid Cancer

  • 8:15 AM – 9:30 AM
  • Description: No description provided.

Sign up for alerts and stay informed on more upcoming conferences and recaps of conferences once they conclude.

Copyright © 2025 Guideline Central, all rights reserved.